Loading clinical trials...

Effects of Pomegranate Juice on Ulcerative Colitis | Clinical Trials | Clareo Health

RECRUITINGNA

Effects of Pomegranate Juice on Ulcerative Colitis

Effect of Pomegranate Juice on Gut Inflammation, Quality of Life and the Gut Microbiome in Patients With Ulcerative Colitis: A Pilot Study

NCT07115862•University of California, Los Angeles

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether consumption of 237 ml of pomegranate juice daily for 8 weeks will: 1. lower inflammation (in the gut as well as generally in the body) and improve your overall quality of life 2. affect the microbes living in the gut (gut microbiota)

Detailed Description

the study is aimed at evaluating the effects of pomegranate juice (PomJ) on: 1) gut inflammation (fecal calprotectin and Simple Clinical Colitis Activity Index) and quality of life; 2) circulating inflammatory markers (e.g., hs-CRP, IL-6, IL-10, TNF-a, IL-1b, IL-8, LBP, LPS) and markers of oxidative stress (blood and urine malondialdehyde (MDA)) and 3) gut microbiota composition and functionality (urinary and circulating urolithin metabolites, fecal SCFAs/BAs, blood LBP and LPS, etc.). We will perform a randomized, controlled, 16-week trial to generate preliminary evidence on the effects of PomJ consumption in patients with mild-to-moderate UC. Participants will be randomly assigned to one of two groups: intervention group and delayed start group. The study will involve 2 phases, each lasting for 8 weeks. During Phase 1, the intervention group will consume 237 ml of PomJ daily, while the delayed start group will follow their habitual diet. Data generated from the delayed start group during Phase 1 will serve as the control for the study. During Phase 2, the intervention group will stop consuming PomJ and switch to consuming their habitual diet, while the delayed start group will consume 237 ml of PomJ daily for 8 weeks. Data generated from the intervention group during Phase 2 will serve as a follow-up to explore whether the effects of PomJ consumption persist after consumption is stopped (this will be an exploratory outcome).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•• Adults ≥ 18 yo
•* Following a low-polyphenol and fiber diet (\< 3 servings of fruits/vegetables per day)
•* Mild-to-moderate UC at the time of screening (2 ≤ partial Mayo scores ≤ 5)
•* Supportive evidence of active inflammation (hsCRP \>1 mg/L, fecal calprotectin \>50 µg/g stool, or abnormal lower endoscopy) in individuals with biopsy-proven UC
•* Patients on 5-aminosalicylates must be on a stable dose for ≥ 4 weeks prior to screening
•* Patients on treatment with immunosuppressive therapy (e.g., azathioprine/6-mercaptopurine, methotrexate) must be on stable dose for 8 weeks prior to baseline visit
•* At the time of baseline visit, patients may be on no more than 20 mg/day of prednisone and 9 mg/day of budesonide MMX
•* Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.

Exclusion Criteria

•• Non-English speaker
•* Vegetarian/vegan
•* Known pomegranate allergy
•* Documented chronic disease besides UC, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass
•* Patients with CD, indeterminate/severe to fulminant colitis
•* History of colectomy or colonic dysplasia
•* Presence of ileal pouch or ostomy
•* Evidence of active bacterial or viral gastroenteritis as indicated by positive stool studies for ova \& parasites, Clostridium difficile, and stool culture
•* Recent hospitalizations (within 2 weeks of screening) for UC requiring IV steroids
•* Presence of the following labs indicative of severe colitis: a. Hemoglobin \< 8.0 g/dl b. Albumin \< 3.0 g/dl
+10 more criteria

Locations (2)

West Los Angeles VA Medical Center

Los Angeles, California, United States

UCLA Center for Human Nutrition

Los Angeles, California, United States

Key Dates

Start Date

October 15, 2025

Primary Completion Date

October 15, 2027

Completion Date

October 15, 2027

Last Updated

December 9, 2025

Enrollment

ESTIMATED participants

Conditions

Ulcerative Colitis (Disorder)

Interventions

pomegranate juice -> habitual diet

OTHER

habitual diet -> pomegranate juice

OTHER

Contacts

Tatiana Diacova, PhD, MS, RDN

CONTACT

310-206-8292 tdiacova@mednet.ucla.edu

Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy

NCT07089771

Inflammatory Bowel Disease (IBD)Ulcerative Colitis (Disorder)+2 more

View study

NOT_YET_RECRUITINGNA

Partial Enteral Nutrition to Prevent Weight Loss and Sarcopenia in IBD Patients at Nutritional Risk - SIMBA

NCT07433946

Ulcerative Colitis (Disorder)Crohn Disease+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions